Freeline Therapeutics climbs after healthcare group Syncona's unit reports majority stake
28/03/2022 12:44
** Shares of drug developer FRLN.O rise as much as 28.5%
to $1.44 before the bell - on track to hit highest levels in
over two months, if gains hold
** Late on Friday, London-based Syncona Portfolio Ltd
reported a stake of 62.3% in FRLN (https://bit.ly/3uxYKZk)
** According to the regulatory filing, stake consists of
~15.9 million ordinary FRLN shares and ~22 million American
depositary shares of FRLN
** Syncona Portfolio says, in filing, it acquired ~19 mln
ADSs of FRLN at purchase price of $1.05/ADS on March 15 through
direct offering urn:newsml:reuters.com:*:nGNX4g8kcG
** Syncona Portfolio is a unit of Syncona Holdings, which is
owned by the healthcare group Syncona Limited SYNCS.L
** Up to Friday's close, FRLN down 43.4% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))